- Cytokinetics Incorporated (NASDAQ:CYTK) announced the full results from the METEORIC-HF Phase 3 trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF).
- METEORIC-HF evaluated the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity.
- After 20 weeks of treatment, no effect of omecamtiv mecarbil on exercise capacity was observed versus placebo.
- Also See: Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients.
- Patients treated with omecamtiv mecarbil had an average change from baseline in pVO2 of -0.2 ml/kg/min compared to 0.2 ml/kg/min for patients on placebo.
- No beneficial effect was observed in any of the secondary endpoints, including change in total workload during exercise, change in ventilatory efficiency, and change in daily physical activity.
- Additional data from GALACTIC-HF were also presented, including a healthcare resource utilization analysis and the effect of omecamtiv mecarbil in hospitalized patients compared to outpatients.
- In the selected subgroup of the GALACTIC-HF trial, omecamtiv mecarbil was associated with significant reductions in risk of a first heart failure event (relative risk reduction (RRR) 15%, absolute risk reduction (ARR) 3.8, number needed to treat (NNT) 26.2), total HF events (RRR 17%, ARR 6.8, NNT 14.7), and cumulative heart failure events.
- The rate of the primary outcome was higher in hospitalized patients in the placebo group (38.3/100 person-years [PY]) than in outpatients (23.1/100 PY) with an adjusted hazard ratio (HR) of 1.21.
- Price Action: Friday, CYTK shares closed 4.27% higher at $38.38.
SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $21
SVB Leerink analyst Roanna Ruiz maintains Myovant Sciences (NYSE:MYOV) with a Market Perform and lowers the price target from $23 to $21.
